An analogous successful approach can be seen in the treatment of acute promyelocytic leukemia (APL), where the combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) targets different moieties of the PML-RARα fusion oncoprotein [52,53]. This evidence concerns the gene RARA and acute promyelocytic leukemia.